Skip to Content
Dr. Paul explains MS to the newly diagnosed. Watch video >>

Tysabri (natalizumab) Disease Interactions

There are 3 disease interactions with Tysabri (natalizumab):

Major

Natalizumab (Includes Tysabri) ↔ Pml

Severe Potential Hazard, Moderate plausibility

Applies to: Immunodeficiency, Infection - Bacterial/Fungal/Protozoal/Viral

Natalizumab increases the risk of progressive multifocal leukoencephalopathy (PML) and is contraindicated in patients who have or have had PML. Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with natalizumab. Healthcare professionals should monitor patients on natalizumab for any new sign or symptom suggestive of PML. Withhold natalizumab dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.

Moderate

Natalizumab (Includes Tysabri) ↔ Liver Dysfunction

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Postmarketing reports have associated the use of natalizumab with severe hepatic toxicity, including acute liver failure requiring transplant. Natalizumab should be discontinued in patients with jaundice or other evidence of significant liver injury and appropriate therapy should be instituted according to clinical guidelines.

Moderate

Natalizumab (Includes Tysabri) ↔ Meningitis

Moderate Potential Hazard, Moderate plausibility

Applies to: Herpes Zoster Meningitis

Natalizumab increases the risk of developing encephalitis and meningitis caused by herpes simplex and varicella zoster viruses. It is recommended to monitor patients receiving natalizumab for signs and symptoms of meningitis and encephalitis. If herpes encephalitis or meningitis occurs, treatment should be discontinued, and appropriate treatment for herpes encephalitis/meningitis should be administered.

Tysabri (natalizumab) drug Interactions

There are 211 drug interactions with Tysabri (natalizumab)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide